

Supplementary Table 2. Incidence rate and risk of CVD according to LDL-C levels depending on statin treatment

Outcome	LDL-C, mg/dL	Total		Statin nonuser (n=158,866)		Statin user (n=89,136)		Statin nonuser at event ^a	
		IR	HR (95% CI)	IR	HR (95% CI)	IR	HR (95% CI)	IR	HR (95% CI)
Composite	<70	9.15	1 (reference)	9.25	1 (reference)	9.08	1 (reference)	8.46	1 (reference)
	70–<100	9.75	1.12 (1.07–1.17)	9.84	1.13 (1.06–1.21)	9.63	1.12 (1.05–1.19)	9.25	1.16 (1.07–1.26)
	100–<130	10.08	1.20 (1.15–1.26)	10.07	1.21 (1.13–1.29)	10.12	1.22 (1.14–1.31)	9.68	1.26 (1.17–1.36)
	130–<160	10.89	1.32 (1.26–1.39)	10.96	1.33 (1.24–1.43)	10.70	1.34 (1.24–1.44)	10.49	1.38 (1.27–1.5)
	160–<190	11.79	1.46 (1.37–1.55)	12.30	1.50 (1.38–1.64)	11.12	1.43 (1.30–1.57)	11.91	1.58 (1.41–1.76)
	≥190	13.38	1.65 (1.51–1.80)	15.84	1.91 (1.69–2.16)	11.42	1.45 (1.28–1.64)	15.96	2.07 (1.76–2.43)
	<i>P</i> for trend		<0.001		<0.001		<0.001		<0.001
MI	<70	3.04	1 (reference)	2.93	1 (reference)	3.13	1 (reference)	2.43	1 (reference)
	70–<100	3.27	1.17 (1.08–1.27)	2.99	1.11 (0.99–1.25)	3.68	1.27 (1.14–1.41)	2.60	1.16 (1.01–1.35)
	100–<130	3.43	1.29 (1.19–1.40)	3.31	1.29 (1.15–1.45)	3.76	1.33 (1.19–1.49)	2.98	1.4 (1.22–1.62)
	130–<160	3.7	1.42 (1.30–1.54)	3.75	1.49 (1.32–1.67)	3.55	1.29 (1.13–1.47)	3.25	1.56 (1.34–1.81)
	160–<190	4.56	1.77 (1.60–1.96)	4.76	1.91 (1.65–2.20)	4.30	1.62 (1.40–1.89)	4.50	2.20 (1.82–2.65)
	≥190	5.37	2.03 (1.77–2.33)	6.38	2.50 (2.06–3.04)	4.55	1.69 (1.39–2.06)	5.89	2.83 (2.16–3.71)
	<i>P</i> for trend		<0.001		<0.001		<0.001		<0.001
Stroke	<70	6.49	1 (reference)	6.62	1 (reference)	6.38	1 (reference)	6.24	1 (reference)
	70–<100	6.82	1.09 (1.03–1.15)	7.15	1.14 (1.05–1.23)	6.34	1.03 (0.96–1.12)	6.85	1.15 (1.05–1.26)
	100–<130	6.99	1.14 (1.08–1.21)	7.10	1.17 (1.08–1.26)	6.68	1.13 (1.04–1.23)	6.89	1.20 (1.10–1.31)
	130–<160	7.61	1.26 (1.19–1.34)	7.64	1.27 (1.17–1.38)	7.53	1.32 (1.21–1.45)	7.44	1.30 (1.18–1.43)
	160–<190	7.75	1.31 (1.22–1.42)	8.00	1.32 (1.19–1.47)	7.42	1.34 (1.20–1.50)	7.69	1.34 (1.17–1.53)
	≥190	8.49	1.45 (1.30–1.61)	10.02	1.64 (1.41–1.91)	7.25	1.30 (1.12–1.51)	10.35	1.76 (1.45–2.14)
	<i>P</i> for trend		<0.001		<0.001		<0.001		<0.001

CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; IR, incidence rate; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction.

^aStatin nonuser at event: Among the non-statin users at baseline (n=158,866), those who were prescribed statins during the follow-up period were dropped out. The events that occurred before taking statins were included in the analysis, and those that occurred after taking statins were excluded. Finally, a total of 89,773 people was dropped out during the follow-up period.